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Abstract 
 
Background: 
There has been no consensus which system, either Cancer of the Liver Italian Program 
(CLIP) or Japan Integrated Staging (JIS) system, is suitable to predict the prognosis of 
hepatocellular carcinoma (HCC) patients who underwent transcatheter arterial 
chemoembolization (TACE) as initial therapy. 
Purpose: 
To retrospectively compare the usefulness of CLIP and JIS system in predicting and 
stratifying the prognosis of HCC patients treated by TACE. 
Materials and Methods: 
Between 1995 and 2005, consecutive 728 patients with untreated HCC who underwent 
TACE in our institute were selected for this study. The survival rate and its prognostic 
factors were assessed by multivariate analysis. Patients were stratified according to the 
two systems, and their survival rates between the scores were compared. 
Results: 
The mean follow-up period was 1689 days. The one-year, 3-year, 5-year, and 10-year 
survival rates were 83.1%, 55.1%, 34.7%, 12.8%, respectively. 
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Both systems stratified the prognosis of patients well, but slightly better in CLIP system 
as compared to in JIS. As for multivariate factor analysis, less severe Child-Pugh 
classification (p<.001), simple tumor morphology (p<.001), absence of portal vein 
invasion (p<.001), and lower alpha- fetoprotein (AFP) level (p<.001) were suggested to 
be independent indicators for favorable survival rate. All of these independent factors 
were included in the CLIP, whereas JIS system lacked AFP level. Furthermore, the 
likelihood χ2-test value was higher, and the Akaike information criterion value was 
lower for CLIP than for JIS system. 
Conclusion: 
CLIP is more suitable than JIS for predicting prognosis of patients with HCC who 
would undergo TACE in Japanese population. 
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Introduction    
Hepatocellular carcinoma (HCC) mainly involves patients already affected with 
chronic hepatitis or liver cirrhosis due to hepatitis B or C viral infection (1) or alcohol 
(2). Therefore, the prognostic assessment and choice of therapeutic modalities, such as 
liver resection, local ablation therapy, transcatheter arterial chemoembolization (TACE), 
and liver transplantation strongly depends not only on the grade of cancer spread (tumor 
staging), but also on the grade of residual liver function (liver disease stage) (3).  
So far, several integrated staging or scoring systems for HCC have been proposed, 
including Okuda stage in 1985 (4), Cancer of the Liver Italian Program (CLIP) Scoring 
System in 1998 (5, 6), Barcelona Clinic Liver Cancer (BCLC) Staging System in 1999 
(7), Japan Integrated Stage (JIS) Score in 2004 (8), Tokyo Score in 2005 (9), Modified 
JIS Score in 2006 (10), and Biomarker Combined JIS Staging Score in 2008 (11), and 
revised BCLC in 2014 (12).  
 Generally, TACE has been considered to be indicated for those at BCLC stage B, 
which is defined as an intermediate-stage disease that consists of heterogeneous patients 
(13).  Furthermore, patients who are not at BCLC stage B, namely stage A or C, are 
sometimes referred to our department for TACE in actual clinical practice.  To 
adequately determine the indication of TACE, detailed stratification of these patients 
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based on their respective prognosis would be mandatory, because those actually treated 
by TACE are highly heterogeneous in terms of tumor staging and liver disease staging 
as well (14).  Among the integrated staging or score systems as mentioned above, 
CLIP and JIS score systems have detailed stratification, and have been most widely 
accepted in Japan. The former consists of one patient factor and 3 tumor factors, 
scoring from 0 to 6 (Table 1), and the latter consists of one patient factor and 5 tumor 
factors, scoring from 0 to 5 (Table 2). However, there is no worldwide consensus yet 
regarding which system is more suitable to patients with HCC treated by TACE. 
The purpose of this study was to retrospectively compare the usefulness of CLIP and 
JIS systems in stratifying the prognosis of HCC patients who had undergone TACE as 
initial therapy in our institute. 
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Materials and Methods  
 Our institutional review board waved to obtain informed consent from the patients 
who were recruited for this study because of its retrospective nature.   
 
Patients and data collections 
939 consecutive patients underwent initial TACE for HCC in our institute between 
January 1995 and April 2005. Indication of TACE was basically in concordance with 
the “intermediate stage” of BCLC staging system, namely, patients who have 
Child-Pugh grades A and B liver function, and are considered contraindicated to 
surgical resection or percutaneous therapies. However, patients who were theoretically 
indicated for percutaneous therapies but whose HCC were located at difficult sites to 
access by percutaneous approach, or those who were initially arranged for surgical 
resection but refused later, or were considered contraindicated for surgery due to poor 
systemic condition including cardiac or respiratory insufficiency, were also referred to 
our department for TACE, as an alternative to curative treatments or as a palliative 
treatment.  
 Angiographic reports and medical records of these 939 patients were retrospectively 
reviewed by one of the authors (HU), and CLIP and JIS scores and survival after initial 
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TACE were recorded. In our institute, the tumor morphology, presence of portal vein 
thrombosis or bile duct invasion, the liver function reserve to determine Child-Pugh 
grades, the serum level of alfa-fetoprotein (AFP) before TACE, diameter of the largest 
HCC treated, and multiplicity of HCC lesions, which are the constituents of CLIP and 
JIS system, were routinely documented in the angiography records, in addition to usual 
clinical information.  Among all of the patients, those who had been treated with other 
therapies before initial TACE, including surgical resection and percutaneous therapies, 
were excluded; those with lymph nodal and distant metastases were also excluded. 
After the initial TACE, recurrent diseases were usually treated with additional TACE 
on demand with or without palliative RFA. Those who underwent hepatectomy after 
initial TACE were excluded. 
 
TACE procedure 
Written informed consent was obtained prior to the procedure, and TACE was 
performed in a conventional fashion as previously reported (15).  After performing 
diagnostic hepatic angiography, a 2.4 Fr. microcatheter (Micro Feret-18, William Cook, 
Bjaeverskov, Denmark) using a 0.014 inch microguidewire (Micromate guidewire, 
Terumo Clinical Supply, Gifu, Japan) was then introduced into the feeding arteries. 
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TACE was performed for HCCs under superselective catheterization into a peripheral 
hepatic artery (subsegmental or segmental artery, whenever possible) using a 
microcatheter according to the distribution of HCC.  An oil suspension was prepared 
by mixing 2-5ml of iodized oil (Lipiodol Ultra-Fluid, Guerbet Japan, Tokyo, Japan）and 
anticancer agents dissolved in contrast medium (Iopamiron 300 mgI/ml, Bayer Yakuhin, 
Osaka, Japan) at half the volume of the iodized oil. The anticancer drugs included 10-20 
mg of doxorubicin hydrochloride (Adriamycin, Nippon Kayaku, Tokyo, Japan) or 10-30 
mg of epirubicin hydrochloride (Farmorubicin, Pfizer Japan, Tokyo, Japan). Just before 
use, the suspension was shaken by hand for a few minutes for better mixing. The 
iodized oil suspension was thus injected into hepatic arteries until all parts of the tumor 
were filled (2-10 ml). Gelatin sponge particles (Spongel, Astellas Pharma, Tokyo, 
Japan), approximately 500 μm to 1 mm in size, were then introduced until the arterial 
blood supply to the aimed volume of the tumor was completely stopped.  After TACE, 
patients were followed up by dynamic CT every three to four months at the outpatient 
clinic. 
 
Assessments and Statistical analysis 
728 patients were stratified according to the CLIP or JIS scores, and their survival 
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rates between the scores were compared using Cox proportional hazard model (16, 17).  
All patient and tumor factors included in both CLIP and JIS (Table 1) were assessed by 
univariate and multivariate analyses to clarify significant factors among them. The 
system, as a whole, was also assessed using multivariate analysis, and also by likelihood 
χ2-test and Akaike information criteria (18) for the prognostic stratification and 
homogeneity assessment for these two systems for comparison, using IBM SPSS 
software program (version 22, IBM Japan, Tokyo, Japan). All other analyses were 
performed using the SAS statistical software program (version 9.3, SAS Japan, Tokyo, 
Japan). 
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Results 
 
Patients and overall survival 
Among these 939 patients, 211 patients were excluded, the details of which are 
shown in Fig.1, and thus, remaining 728 cases finally formed our patient population.   
Table 2 shows the demographic information of the all patients. The follow-up period 
ranged from 4 to 5093, with a median of 1248 days. The overall survival rates for 1 year, 
3 years, 5 years, 7 years, and 10 years were 83.1%, 55.1%, 34.7%, 23.3%, and 12.8%, 
respectively.  
 
Survival by CLIP and JIS Score systems 
There were 150/239/198/80/40/19/2 patients in CLIP scores 0/1/2/3/4/5/6, 
respectively, and 57/177/266/147/68/13 patients in JIS scores 0/1/2/3/4/5, respectively.  
Table 3 shows the cumulative survival rates according to CLIP Scores. There were 
statistically significant differences in survival rates between the score groups except for 
between scores 5 and 6. Figure 2 shows the survival curves of patients according to 
CLIP Scores. 
Table 4 shows the cumulative survival rates according to JIS Scores. There were 
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statistically significant differences between the score groups except for between scores 
0 and 1 and also between 4 and 5. Figure 3 shows the survival curves of patients 
according to JIS Scores. 
 
Analysis of prognostic factors and the models 
The results of univariate and multivariate analyses of factor analysis were shown in 
Table 5.   
The multivariate analyses revealed less severe Child-Pugh classification (p<.001), 
simple tumor morphology (p<.001), absence of portal vein invasion (p<.001), and lower 
AFP level (p<.001) as independent indicators for favorable survival rate, all of which 
are included in CLIP, but not in JIS system.  
   The univariate and multivariate analyses of CLIP and JIS Score model as a whole 
were shown in Table 6. Multivariate model analysis suggested CLIP, but not JIS, was an 
independently significant system to correlate with the survival.  
   Table 7 shows the prognostic stratification and homogeneity of CLIP and JIS Score 
model. The likelihood χ2-test value was higher, and the Akaike information criterion 
value was lower for the CLIP system than for JIS system, indicating the superiority of 
CLIP system over JIS in terms of discriminatory ability and homogeneity.  
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Discussion  
There have been several staging systems proposed to predict the prognosis of patients 
with HCC who undergo particular choice of treatment.  Huang et al. (19) reported 
patients who undergo surgical resection would be best stratified by TNM system.  
Vauthey et al. (20) concluded that AJCC/UICC system is the best for those treated with 
transplantation.  Guglielmi et al. (21), on the other hand, reported that BCLC system is 
the best system to predict the prognosis of patients who receive RFA as a treatment of 
choice. To predict prognosis of patients who undergo TACE, several new staging 
systems have been proposed (13, 14), but these are rather complicated.  We simply 
applied pre-existing CLIP and JIS systems to see whether these systems can stratify the 
prognosis of patients who are treated with TACE   
1, 3, 5, 7, and 10 year overall survival rates of our study population were 83.1%, 
55.1%, 34.7%, 23.3%, and 12.8%, respectively, which are almost comparable to or even 
better than previously reported data in Western countries (22) or in Japan (23). 
We tested all patient and tumor factors which are included in both CLIP and JIS, and 
found all independently significant factors were included in CLIP but not in JIS (Table 
5).  We also compared these two systems directly, by multivariate analysis, likelihood 
χ2 test, and Akaike information criterion, and successfully showed CLIP is superior to 
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JIS (Tables 6 and 7). Thus, according to our results of both factor analysis and model 
analysis, CLIP was suggested to be more suitable to predict prognosis of 783 HCC 
patients who undergo TACE, rather than JIS.  This is reasonable, because JIS Score 
was originally proposed for evaluation of patients undergoing local therapies，such as 
PEIT, MCT or RFA (24, 25).  
One limitation of this study, other than the retrospective nature, is that we assessed 
only CLIP and JIS systems, excluding other recently proposed systems, such as Tokyo 
scores (9) and modified JIS (10, 11). This is because previous cases, typically those 
before 2000, occasionally lacked relatively newly developed laboratory data, such as 
prothrombin induced by vitamin K absence or antagonist, or detailed imaging data of 
these patients were no longer available, both of which are required to assess the patients 
according to the recently proposed systems. Further investigation including these 
information may establish better system to assess the prognosis of patients with HCC 
who undergo TACE as initial therapy.  Second, because we recruited patients over 10 
years between 1995 and 2005, it is possible that technological improvement during the 
study period might have biased our results.  Third, because we retrospectively 
recruited all patients treated with TACE, our patient population included those who are 
not at the intermediate stage according to BCLC classification, as mentioned earlier.  
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We, therefore, are now conducting a next study in which the role of CLIPS and JIS 
scoring systems is elucidated in stratifying the patients with HCC who are strictly at 
BCLC stage B in our patient population. Finally, the etiology of HCC, and its treatment 
strategies as well, is different in different countries (2), and therefore, our results may 
not be generalized or directly applicable to patients in other parts of the world.  
 In conclusion, based on our single center study using Japanese patients who were 
initially treated with TACE, CLIP system was shown to be more suitable than JIS 
system for predicting prognosis of patients with HCC who undergo TACE as initial 
therapy. 
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Table 1 Factors included in Cancer of the liver Italian program (CLIP) and Japan Integrated Staging (JIS) systems 
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Table 2 Demographic information of the 728 patients 
 
 
LCSGJ: the liver cancer study group of Japan 
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Table 3 Survival according to Cancer of the Liver Italian Program (CLIP) scores 
 
N.S.: not significant 
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Table 4 Survival according to Japan Integrated Stage (JIS) score 
 
N.S.: not significant 
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Table 5 Prognostic factor analysis 
 
 
LCSGJ: the liver cancer study group of Japan, N.S.: not significant, CI: confidence interval, AFP: alpha-fetoprotein 
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Table 6 Model analysis 
 
CLIP: Cancer of the Liver Italian Program, JIS: Japan Integrated Stage, CI: confidence interval, N.S.: not significant 
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Table 7 Prognostic stratification and homogeneity analysis 
 
CLIP: Cancer of the Liver Italian Program, JIS: Japan Integrated Stage, CI: confidence interval, N.S.: not significant 
* Higher χ2 indicates better model for discriminatory ability, homogeneity, and monotonicity. 
** Lower AIC indicates better model for discriminatory ability. Difference in AIC > 2 is considered significant. 
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Figure Legends 
Fig.1 Flow diagram of patient selection.  TACE: transcatheteral arterial 
chemoembolization, HCC: hepatocellular carcinoma, PMCT: percutaneous microwave 
coagulation therapy, PEIT: percutaneous ethanol injection therapy, RFA: radiofrequency 
ablation 
 
Fig.2 Survival stratification according to CLIP score.  CLIP: Cancer of the Liver 
Italian Program, N.S.: not significant 
 
Fig.3 Survival stratification according to JIS score.  JIS: Japan Integrated Stage, N.S.: 
not significant 
 
 
 
HCC patients who underwent TACE 
as initial therapy 
between January 1995 and April 2005 
(n=939) 
Excluded patients (n=211) 
 
・Previous treatment for HCC (n=156) 
 Hepatectomy (n=11) 
 Percutaneous local therapy  
  PMCT (n=1) 
  PEIT (n=105) 
  RFA (n=47) 
・Treatment after initial TACE (n=5) 
 Hepatectomy (n=4) 
 Liver transplantation (n=1) 
・Lymph nodal and distant metastases (n=14) 
・Lacking data (n=36) 
Eligible patients 
between January 1995 and April 2005 
(n=728) 
Flow diagram of patient selection.   TACE: Transcatheter arterial chemoembolization , HCC: hepatocellular 
carcinoma, PMCT: Percutaneous microwave coagulation therapy, PEIT: percutaneous ethanol injection 
therapy, RFA: radiofrequency ablation 
Figure 1   Flow diagram of patient selection 
Survival stratification according to CLIP score.   CLIP: Cancer of the Liver Italian Program, N.S.: not significant 
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Figure 2   Survival stratification according to CLIP scores 
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Figure 3   Survival stratification according to JIS scores 
